Sartorius grew third-quarter revenue by 9.0% in constant currencies before tariff compensation to customers. Underlying EBITDA margin increased 90 basis points year over year to 30.2%. Both metrics exceeded Vara-compiled consensus. Management confirmed its full-year guidance.
Sartorius AG’s product portfolio in CGT allows it to capitalize on long-term growth, should these therapies achieve widespread adoption.
The high growth in the biopharma market increases the risk of greater competition from better-capitalized peers who have a broader product offering.
|
Metric
|
SRT
|
MRK
|
MTD
|
|---|---|---|---|
Price/Earnings (Normalized) | 62.83 | 17.63 | 37.39 |
Price/Book Value | 5.12 | 2.05 | 2,621.86 |
Price/Sales | 4.04 | 2.93 | 8.27 |
Price/Cash Flow | 20.50 | 13.59 | 31.89 |
|
Metric
|
SRT
|
MRK
|
MTD
|
|---|---|---|---|
Quick Ratio | 0.43 | 0.99 | 0.65 |
Current Ratio | 1.07 | 1.69 | 1.12 |
Interest Coverage | 4.03 | 7.22 | 16.83 |
|
Metric
|
SRT
|
MRK
|
MTD
|
|---|---|---|---|
Return on Assets (Normalized) | 3.58% | 4.75% | 26.25% |
Return on Equity (Normalized) | 12.52% | 8.32% | — |
Return on Invested Capital (Normalized) | 5.41% | 6.65% | 48.46% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Intuitive Surgical Inc
ISRG
| LOCK|Kl^@!cH | LOCK|h$ | $151B | |||
| Becton Dickinson & Co
BDX
| LOCK|N$t | LOCK|%P>h$ | $53B | |||
| ResMed Inc
RMD
| LOCK|c?DVg^BD | LOCK|qBS%z | $35B | |||
| Alcon Inc
ALC
| LOCK|#&@m@jQ | LOCK|Vfc>$ | $33B | |||
| Medline Inc Ordinary Shares - Class A
MDLN
| LOCK|DVW?YH% | LOCK|v#b@& | $31B | |||
| West Pharmaceutical Services Inc
WST
| LOCK|vsJ$X%W | LOCK|Rd | $28B | |||
| Solventum Corp
SOLV
| LOCK|dnSL@# | LOCK|Cb | $15B | |||
| Baxter International Inc
BAX
| LOCK|#y | LOCK|gL$GJ | $13B | |||
| Repligen Corp
RGEN
| LOCK|ZpVnh#yW | LOCK|zMx&& | $11B | |||
| The Cooper Companies Inc
COO
| LOCK|%!s>@^^ | LOCK|s#Rr< | $11B |
United States